Real-world Outcomes of Anti-EGFR Therapy in Advanced Non-small Cell Lung Cancer EGFR Mutated in Peru

Overview

Journal Thorac Cancer

Specialties Oncology
Pulmonary Medicine

Date 2022 Nov 12

PMID 36369763

Authors

Marco Galvez-Nino

Rossana Ruiz

Katia Roque

Ofelia Coanqui

Natalia Valdivieso

Mivael Olivera

Apar Kishor Ganti

Luis Mas

Affiliations

Soon will be listed here.

Abstract

Background: Despite the advances in the management of advanced non-small cell lung cancer (NSCLC), the access to genetic profiling and target therapies remains a challenge in Latin America, even in countries with a higher rate of targetable mutations. The aim of this study is to evaluate the clinical outcomes of anti-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) treatment in a Peruvian real-world setting.

Methods: This is a retrospective study of recurrent or advanced NSCLC EGFR mutated patients diagnosed and treated with anti-EGFR TKI at Instituto Nacional de Enfermedades Neoplásicas (INEN) between January 1, 2015 to December 31, 2020. The outcomes were objective response rate (ORR), progression free survival (PFS), and overall survival (OS).

Results: We identify 613 stage IV or recurrent NSCLC patients who were tested for EGFR mutations and found a pathogenic mutation in 39.5% of patients. Only 51.2% of them received anti-EGFR TKI as institutional treatment. ORR was 58%, after median follow-up of 32 months, the estimated median PFS was 13.9 months (11.1-16.7 months), and the estimated median OS was 21.7 months (18.5-24.9 months). No differences were found in PFS according to line of treatment or brain metastases at diagnosis (p = 0.46 and p = 0.07, respectively), respect to OS there were no differences line of treatment (p = 0.12), significant difference were found in presence of brain metastases (p = 0.006).

Conclusion: Our study demonstrates that erlotinib for advanced NSCLC harboring EGFR-activating mutations is effective even in patients usually excluded from clinical trial, like those previously exposed to one or more lines of chemotherapy or with brain metastases.

Citing Articles

Real-world outcomes of anti-EGFR therapy in advanced non-small cell lung cancer EGFR mutated in Peru.

Galvez-Nino M, Ruiz R, Roque K, Coanqui O, Valdivieso N, Olivera M Thorac Cancer. 2022; 14(1):61-67.

PMID: 36369763 PMC: 9807447. DOI: 10.1111/1759-7714.14714.

References

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

Raez L, Cardona A, Arrieta O, Lopes G . Lung Cancer Disparities in Hispanics: Molecular Diagnosis and Use of Immunotherapy. JCO Glob Oncol. 2020; 6:784-788. PMC: 7328112. DOI: 10.1200/GO.20.00004. View

Shi Y, Au J, Thongprasert S, Srinivasan S, Tsai C, Khoa M . A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol. 2014; 9(2):154-62. PMC: 4132036. DOI: 10.1097/JTO.0000000000000033. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Soria J, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee K . Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 378(2):113-125. DOI: 10.1056/NEJMoa1713137. View

Wu Y, Zhou C, Liam C, Wu G, Liu X, Zhong Z . First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol. 2015; 26(9):1883-1889. DOI: 10.1093/annonc/mdv270. View

Martin C, Cuello M, Barajas O, Recondo G, Aruachan S, Perroud H . Real-world evaluation of molecular testing and treatment patterns for EGFR mutations in non-small cell lung cancer in Latin America. Mol Clin Oncol. 2021; 16(1):6. PMC: 8647188. DOI: 10.3892/mco.2021.2439. View

Gerson R, Zatarain-Barron Z, Blanco C, Arrieta O . Access to lung cancer therapy in the Mexican population: opportunities for reducing inequity within the health system. Salud Publica Mex. 2019; 61(3):352-358. DOI: 10.21149/10118. View

Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E . Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012; 13(3):239-46. DOI: 10.1016/S1470-2045(11)70393-X. View

10.

Raez L, Cardona A, Santos E, Catoe H, Rolfo C, Lopes G . The burden of lung cancer in Latin-America and challenges in the access to genomic profiling, immunotherapy and targeted treatments. Lung Cancer. 2018; 119:7-13. DOI: 10.1016/j.lungcan.2018.02.014. View

11.

Kurtovic-Kozaric A, Vranic S, Kurtovic S, Hasic A, Kozaric M, Granov N . Lack of Access to Targeted Cancer Treatment Modalities in the Developing World in the Era of Precision Medicine: Real-Life Lessons From Bosnia. J Glob Oncol. 2018; 4:1-5. PMC: 6180810. DOI: 10.1200/JGO.2016.008698. View

12.

Ma C, Wei S, Song Y . T790M and acquired resistance of EGFR TKI: a literature review of clinical reports. J Thorac Dis. 2012; 3(1):10-8. PMC: 3256494. DOI: 10.3978/j.issn.2072-1439.2010.12.02. View

13.

Howlader N, Forjaz G, Mooradian M, Meza R, Kong C, Cronin K . The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020; 383(7):640-649. PMC: 8577315. DOI: 10.1056/NEJMoa1916623. View

14.

Ruiz R, Galvez-Nino M, Poquioma E, Limache-Garcia A, Amorin E, Olivera M . Lung Cancer in Peru. J Thorac Oncol. 2020; 15(6):891-898. DOI: 10.1016/j.jtho.2020.01.018. View

15.

Galvez-Nino M, Ruiz R, Roque K, Coanqui O, Valdivieso N, Olivera M . Real-world outcomes of anti-EGFR therapy in advanced non-small cell lung cancer EGFR mutated in Peru. Thorac Cancer. 2022; 14(1):61-67. PMC: 9807447. DOI: 10.1111/1759-7714.14714. View

16.

Blom E, Ten Haaf K, Arenberg D, de Koning H . Disparities in Receiving Guideline-Concordant Treatment for Lung Cancer in the United States. Ann Am Thorac Soc. 2019; 17(2):186-194. PMC: 6993802. DOI: 10.1513/AnnalsATS.201901-094OC. View

17.

Lau S, Chooback N, Ho C, Melosky B . Outcome Differences Between First- and Second-generation EGFR Inhibitors in Advanced EGFR Mutated NSCLC in a Large Population-based Cohort. Clin Lung Cancer. 2019; 20(5):e576-e583. DOI: 10.1016/j.cllc.2019.05.003. View

18.

Arrieta O, Cardona A, Martin C, Mas-Lopez L, Corrales-Rodriguez L, Bramuglia G . Updated Frequency of EGFR and KRAS Mutations in NonSmall-Cell Lung Cancer in Latin America: The Latin-American Consortium for the Investigation of Lung Cancer (CLICaP). J Thorac Oncol. 2015; 10(5):838-843. DOI: 10.1097/JTO.0000000000000481. View

19.

Sequist L, Yang J, Yamamoto N, OByrne K, Hirsh V, Mok T . Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013; 31(27):3327-34. DOI: 10.1200/JCO.2012.44.2806. View

20.

Thai A, Solomon B, Sequist L, Gainor J, Heist R . Lung cancer. Lancet. 2021; 398(10299):535-554. DOI: 10.1016/S0140-6736(21)00312-3. View